Table A3.
Chemotherapy elements and treatment regimens used in the A-NB87 trial.
| Stage | Therapy | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| I | Surgery | ||||||||
| IIA | Surgery | If macroscopic residual tumor: second surgery, or radiotherapy | |||||||
| IIB | Surgery | CV | Re-surgery | Radiotherapy | |||||
| IIIA | Surgery | 3–4 × alternating DAMO/MVDOC | Re-surgery | Radiotherapy | (Re-surgery) | ||||
| IIIB | Surgery | 3–5 × alternating DAMO/MVDOC/IPE | Re-surgery | Radiotherapy | Re-surgery | ||||
| IV | Surgery | 4 × alternating MVDOC/IPE | Re-surgery | HDT/TBI/ASCR | Radiotherapy | ||||
| Details on Chemotherapy | |||||||||
| Chemotherapy | Abbreviation | Substance | Dosage | Days Given | |||||
| DAMO | D | dacarbazine | 850 mg/m² | 1 | |||||
| A | doxorubicin | 30 mg/m² | 1, 2 | ||||||
| M | mustargen | 6 mg/m² | 1 | ||||||
| O | vincristine | 1.5 mg/m² | 1 + 5 | ||||||
| MVDOC | M | mustargen | 6 mg/m² | 1 | |||||
| V | teniposide | 150 mg/m² | 1 | ||||||
| D | dacarbacine | 850 mg/m² | 1 | ||||||
| O | vincristine | 1.5 mg/m² | 1 | ||||||
| C | cyclophosphamide | 850 mg/m² | 1 | ||||||
| IPE | I | ifosfamide | 3 g/m² | 1, 2 | |||||
| P | cisplatin | 40 mg/m² | 1–5 | ||||||
| E | etoposide | 150 mg/m² | 3–5 | ||||||
Chemotherapy elements and treatment regimens according to the Austrian Neuroblastoma Trial A-NB87. Staging was done according to Evans criteria: stage I (localized without macroscopic lymphatic node involvement), stage IIA (macroscopic lymphatic node involvement), IIB (macroscopic residual tumor with ipsilateral lymphatic node involvement), IIIA (<2 years of age, ferritin < 300 µg/mL, neuron-specific enolase < 100 ng/mL), IIIB (any positivity of the markers described for stage IIIA), stage 4 (distant metastasized disease).